Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World

Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World

Speaking Engagement
In the wake of FTC v. Actavis and the European Commission's decisions against Lundbeck, J&J and Novartis, pharma patent settlement agreements remain an issue in the US and Europe. Among questions yet to be resolved is how co-promotion and co-marketing, and manufacturing arrangements that are part of patent settlement agreements should be analyzed by antitrust enforcers.

WilmerHale Partner Mark Ford will be a featured speaker on this panel.

Read More About the Event

Speakers

You May Be Interested In

Vierlaenderkonferenz below40 Pre-Event

November 20, 2025
Speaking Engagement

Abuse of Process in International Arbitration Conference

November 20, 2025
Speaking Engagement

IX Oxford Arbitration Day

November 21, 2025
Speaking Engagement
View all Events

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel